A Research Study of MK0633 in Patients With Chronic Obstructive Pulmonary Disease (COPD)(0633-009)(COMPLETED)

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study, Conducted Under In-House Blinding Conditions of MK0633 in Patients With COPD

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00418613

Enrollment

266

Registered

2007-01-05

Start date

2008-01-31

Completion date

2009-03-31

Last updated

2015-09-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Brief summary

A clinical study to evaluate the efficacy and safety of MK0633 in patients with Chronic Obstructive Pulmonary Disease (COPD).

Interventions

DRUGMK633

MK0633 100mg capsules qd for a 12-wk treatment period.

DRUGComparator: Placebo (unspecified)

MK0633 100mg Pbo capsules for a 12-wk treatment period

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

40 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Documented COPD defined by clinical history and spirometry, with symptoms including dyspnea, wheezing, chest tightness, cough, sputum production, or nocturnal awakening * Male or postmenopausal females 40 -75 years of age

Exclusion criteria

* Impaired renal function * History of chronic liver disease or persistent liver function test (LFT) abnormalities * History of recent cardiovascular clinical event * Evidence of another clinically significant, active pulmonary disorder such as bronchiectasis or asthma

Design outcomes

Primary

Measure	Time frame
Pulmonary function test data	Measured over 12 weeks

Secondary

Measure	Time frame
Overall daytime symptoms score, total daily beta agonist use, and Chronic Respiratory Disease Questionnaire (CRQ) score	Measured over 12 weeks of treatment

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 30, 2026